PDCD1 and hepatocellular carcinoma: With the widespread concern of locoregional treatment combined with systemic targeted immunotherapy in the treatment of uHCC, more experiments have been conducted to study the efficacy of TACE plus lenvatinib combined with PD-1 for advanced HCC.